Maxime Dely: Platelet Agitation Strengthens Quality and Confidence in Transfusion Medicine
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Platelet concentrate agitation: a technical detail that saves lives
In transfusion medicine, clinical performance begins long before administration. It starts with storage conditions.
Platelet concentrates are stored at 20–24°C under continuous agitation. This is not a logistical choice, but a physiological one. Platelets are living, metabolically active cells: they consume oxygen, produce CO₂, and generate metabolites.
Without agitation, gas exchange decreases, pH drops, metabolism is altered, and hemostatic function deteriorates. Ultimately, this affects cell viability and transfusion efficacy.
Gentle, continuous agitation optimizes oxygenation, limits CO₂ accumulation, and helps maintain biochemical parameters compatible with optimal platelet function.
This measure directly contributes to risk control, both infectious and functional, and therefore to patient safety.
In transfusion medicine, scientific rigor is never optional. Every controlled parameter strengthens quality, safety, and confidence in the transfusion process.
Because behind every platelet concentrate, there is a patient who matters.”
Patricia Epstein, Head of the Hemotherapy Division at Hospital Gral de Agudos “Dr. Carlos G. Durand” and Head of Service at Hospital General de Agudos Juan A. Fernandez, shared this post, adding:
”All points of the process make up the final product, as in any production line….. details matter!!!”
Proceed to the video attached to the post.
Find more posts featuring Maxime Dely on Hemostasis Today.
-
Jul 3, 2026, 13:31Javed Anees: TIA is a Medical Emergency – Not a Benign Warning
-
Jul 3, 2026, 12:46Heghine Khachatryan: 2026 AHA Guideline on the Management of CKM Syndrome
-
Jul 3, 2026, 12:32Shadi Tabibian: Beyond Bleeding – Women Living with von Willebrand Disease
-
Jul 3, 2026, 09:33Abdul Mannan: Not All Type 1 VWD Starts in the VWF Gene
-
Jul 3, 2026, 09:18Aryabhatta Sadhu: Sickle Cell Crisis – When Diagnostics Should Change Therapy
-
Jul 3, 2026, 05:55New Evidence Supports Chromogenic Assays After Hemophilia A Gene Therapy – JTH
-
Jul 3, 2026, 05:50Jacopo Parizzi: Roche’s Non-Malignant Hematology Team Is Looking Ahead to 2027
-
Jul 3, 2026, 05:25Brian A Beh: A New Approach from The George Institute for Global Health Could Transform Stroke Care Before Hospital Arrival
-
Jul 3, 2026, 05:22Deirdre Finnigan: New Insights into Red Blood Cell Biomechanics in Cancer-Associated Anemia